{"product_id":"globusmedical-five-forces-analysis","title":"Globus Medical Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFrom Overview to Strategy Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGlobus Medical faces intense competitive pressures from established orthopedic device makers, moderate supplier leverage due to specialized components, and evolving buyer expectations driven by hospital consolidation; regulatory and reimbursement risks add further complexity. This brief snapshot only scratches the surface — unlock the full Porter's Five Forces Analysis to explore Globus Medical’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Medical Grade Materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe production of spinal implants depends on medical-grade titanium, cobalt-chrome, and PEEK polymers from a small set of certified vendors, with roughly 5–10 suppliers meeting FDA and ISO 13485 standards for implantable devices as of 2025.\u003c\/p\u003e\n\u003cp\u003eThese suppliers face strict quality control and regulatory audits, so Globus Medical cannot rapidly switch providers without revalidation, raising supplier hold-up risk.\u003c\/p\u003e\n\u003cp\u003eAs a result, suppliers exert moderate pricing and lead-time leverage; industry reports in 2024 showed alloy price volatility added 3–6% to implant BOM (bill of materials) costs and extended lead times by 2–8 weeks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Switching Costs for Quality Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh switching costs arise because FDA and international regulators demand extensive validation and documentation for any new supplier of critical components, often adding 6–18 months of testing and $250k–$1M in compliance costs per supplier for medtech firms like Globus Medical (NASDAQ: GMED) in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Robotics Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs Globus Medical expands surgical robotics, it relies on a small set of suppliers for high-precision sensors, actuators, and software sub-systems; fewer than 10 global vendors supply the class of components used in ExcelsiusGPS, boosting supplier bargaining power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property of Sub-Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpintellectual property on imaging sub-components raises supplier power for globus medical integrating third-party proprietary tech creates dependency and can push component costs up per medtech sourcing reports risks margin pressure as integrated software becomes central to next-gen surgical suites.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eProprietary components: supplier-controlled IP\u003c\/li\u003e\n\u003cli\u003eCost impact: 10–25% higher component spend (2024)\u003c\/li\u003e\n\u003cli\u003eStrategic risk: dependency on vendors for software updates\u003c\/li\u003e\n\u003cli\u003eMitigation: license deals or in-house development\u003c\/li\u003e\n\n\u003c\/pintellectual\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Forward Integration Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSuppliers of metals, plastics, and electronics hold some pricing leverage, but forward integration risk is minimal since medical-device manufacturing requires FDA approvals, clinical-trial expertise, and established surgeon sales channels; these barriers stopped \u0026gt;90% of nonmedical entrants in 2024 according to MedTech Insights.\u003c\/p\u003e\n\u003cp\u003eThis weakens suppliers’ leverage, helping Globus Medical (2024 revenue $1.29B) maintain margin control and supplier diversification without fear of direct competition.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinical trial, regulatory cost: high (multi-year, multi-$M)\u003c\/li\u003e\n\u003cli\u003e2024: Globus revenue $1.29B, gross margin ~69%\u003c\/li\u003e\n\u003cli\u003eSupplier concentration: moderate; forward-entry: unlikely\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eModerate supplier leverage: 5–10 vendors, IP\/alloy cost hits vs. $1.29B Globus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold moderate bargaining power: 5–10 certified implant material vendors (2025), IP-linked components raise costs 10–25% (2024), alloy price swings added 3–6% BOM and 2–8 week delays (2024), switching\/regulatory revalidation costs $250k–$1M and 6–18 months; Globus 2024 revenue $1.29B with ~69% gross margin keeps supplier leverage manageable.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCertified suppliers\u003c\/td\u003e\n\u003ctd\u003e5–10\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlloy BOM impact\u003c\/td\u003e\n\u003ctd\u003e+3–6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP cost uplift\u003c\/td\u003e\n\u003ctd\u003e+10–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevalidation cost\/time\u003c\/td\u003e\n\u003ctd\u003e$250k–$1M \/ 6–18m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobus revenue\u003c\/td\u003e\n\u003ctd\u003e$1.29B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Globus Medical, uncovering competitive intensity, supplier and buyer power, threats from substitutes and new entrants, and strategic levers to protect market share and pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces snapshot tailored to Globus Medical—quickly identify competitive pressure points and relief strategies for product pricing, supplier leverage, and emerging entrant risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Healthcare Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe ongoing consolidation of US hospitals into integrated delivery networks and Group Purchasing Organizations (GPOs) has boosted buyer power; the top 25 IDNs now account for roughly 40% of hospital beds, and GPOs negotiate discounts commonly 15–30% off list prices as of 2025. Globus Medical must win placement on restrictive preferred-vendor lists to access these patient flows, often conceding price and contract terms to secure volume. Loss of preferred status can cut implant unit volumes by 20%+ at member systems, pressuring revenues and margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurgeon Influence on Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIndividual surgeons still drive implant choice; surveys show surgeon preference influences 65–75% of spine device selections, so Globus focuses on clinician-led adoption.\u003c\/p\u003e\n\u003cp\u003eGlobus reduces hospital buyer leverage via surgeon training programs and ergonomic instruments; its 2024 K2 cervical system adoption grew revenues 12% year-over-year, reflecting this tactic.\u003c\/p\u003e\n\u003cp\u003eBut value-based purchasing shifts power: US hospital admins cut device costs by 8–15% in 2023, so surgeon preference is now balanced against institutional cost mandates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement Pressures from Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cppublic and private payers set reimbursement for spinal procedures medicare reduced national payment rates fusion bundles by about in pushing hospitals to demand lower implant prices from suppliers like globus medical.\u003e\n\u003cpas hospital margins tighten operating fell to in procurement teams shift cost-focused purchasing increasing price pressure on device makers and demanding bundled pricing or consignment models.\u003e\n\u003c\/pas\u003e\u003c\/ppublic\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice Transparency Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe rise of digital procurement platforms and price-transparency tools lets hospital buyers compare spinal-implant prices across suppliers, cutting information asymmetry that favored device makers; IQVIA and Vizient reported 12–18% greater price sensitivity in 2024 procurement rounds.\u003c\/p\u003e\n\u003cp\u003eGlobus Medical must now justify any premium with demonstrable clinical outcomes and system integration, or risk switching to lower-cost competitors; CMS payment pressures reduced implant margins by ~150–250 bps in 2023–24.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDigital procurement adoption up 27% (2023–24)\u003c\/li\u003e\n\u003cli\u003ePrice sensitivity +12–18% in 2024\u003c\/li\u003e\n\u003cli\u003eImplant margin pressure ~150–250 bps (2023–24)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValue-Based Care Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe shift to value-based care forces hospitals to buy on total episode cost, not device price; buyers push for evidence that robotics and premium implants cut length of stay and revisions.\u003c\/p\u003e\n\u003cp\u003eGlobus Medical must supply robust clinical and economic data—RCTs, real-world evidence, and 90‑\/180‑day cost analyses—to satisfy sophisticated procurement teams.\u003c\/p\u003e\n\u003cp\u003eIn 2024, 43% of US hospitals tied \u0026gt;10% of payments to value metrics, raising demand for long-term ROI data.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHospitals focus on episode cost vs device price\u003c\/li\u003e\n\u003cli\u003eBuyers demand outcomes: shorter stays, fewer revisions\u003c\/li\u003e\n\u003cli\u003eGlobus needs RCTs, RWE, 90\/180‑day cost studies\u003c\/li\u003e\n\u003cli\u003e43% of US hospitals tied \u0026gt;10% payments to value (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIDNs\/GPOs squeeze margins; Globus must deliver RCTs, RWE \u0026amp; 90\/180‑day cost proof\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers (IDNs\/GPOs) now control ~40% of US beds; GPO discounts run 15–30% (2025), cutting implant margins ~150–250 bps (2023–24). Surgeon preference still drives 65–75% of selections, but hospitals tied \u0026gt;10% payments to value rose to 43% (2024), shifting purchase to total episode cost. Digital procurement adoption +27% (2023–24) and price sensitivity +12–18% (2024) force Globus to supply RCTs, RWE, and 90\/180‑day cost data.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIDN share of beds\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO discounts\u003c\/td\u003e\n\u003ctd\u003e15–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgeon influence\u003c\/td\u003e\n\u003ctd\u003e65–75%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals tied to value\u003c\/td\u003e\n\u003ctd\u003e43% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital procurement change\u003c\/td\u003e\n\u003ctd\u003e+27% (2023–24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice sensitivity\u003c\/td\u003e\n\u003ctd\u003e+12–18% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImplant margin pressure\u003c\/td\u003e\n\u003ctd\u003e150–250 bps (2023–24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eGlobus Medical Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Porter’s Five Forces analysis of Globus Medical you'll receive immediately after purchase—no samples, no placeholders, fully formatted and ready for use.\u003c\/p\u003e\n\u003cp\u003eYou're looking at the actual document content: a comprehensive evaluation of supplier power, buyer power, competitive rivalry, threat of new entrants, and threat of substitutes tailored to Globus Medical.\u003c\/p\u003e\n\u003cp\u003eOnce you complete your purchase, you’ll get instant access to this same professionally written file—downloadable and ready for your analysis or presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56746998169977,"sku":"globusmedical-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/globusmedical-five-forces-analysis.png?v=1772194041","url":"https:\/\/matrixbcg.com\/products\/globusmedical-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}